Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-01-01

Reporting Person: Robertson Stephen P. (EVP, General Counsel)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1820	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$13.40	2030-11-16	Common Stock (298924)		Direct
Stock Option (right to buy)	$13.03	2030-12-21	Common Stock (144484)		Direct

Footnotes

F1: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.